全文获取类型
收费全文 | 2354篇 |
免费 | 139篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 101篇 |
妇产科学 | 34篇 |
基础医学 | 362篇 |
口腔科学 | 217篇 |
临床医学 | 202篇 |
内科学 | 565篇 |
皮肤病学 | 84篇 |
神经病学 | 80篇 |
特种医学 | 123篇 |
外科学 | 235篇 |
综合类 | 23篇 |
一般理论 | 1篇 |
预防医学 | 202篇 |
眼科学 | 30篇 |
药学 | 122篇 |
中国医学 | 6篇 |
肿瘤学 | 104篇 |
出版年
2023年 | 15篇 |
2022年 | 40篇 |
2021年 | 54篇 |
2020年 | 50篇 |
2019年 | 60篇 |
2018年 | 72篇 |
2017年 | 57篇 |
2016年 | 52篇 |
2015年 | 85篇 |
2014年 | 110篇 |
2013年 | 123篇 |
2012年 | 192篇 |
2011年 | 177篇 |
2010年 | 128篇 |
2009年 | 90篇 |
2008年 | 130篇 |
2007年 | 87篇 |
2006年 | 91篇 |
2005年 | 91篇 |
2004年 | 70篇 |
2003年 | 69篇 |
2002年 | 67篇 |
2001年 | 54篇 |
2000年 | 35篇 |
1999年 | 43篇 |
1998年 | 33篇 |
1997年 | 37篇 |
1996年 | 30篇 |
1995年 | 35篇 |
1994年 | 28篇 |
1993年 | 40篇 |
1992年 | 15篇 |
1991年 | 17篇 |
1990年 | 21篇 |
1989年 | 20篇 |
1988年 | 21篇 |
1987年 | 17篇 |
1986年 | 21篇 |
1985年 | 17篇 |
1984年 | 6篇 |
1983年 | 9篇 |
1982年 | 9篇 |
1981年 | 14篇 |
1980年 | 6篇 |
1979年 | 6篇 |
1978年 | 6篇 |
1977年 | 9篇 |
1976年 | 13篇 |
1969年 | 9篇 |
1968年 | 6篇 |
排序方式: 共有2514条查询结果,搜索用时 15 毫秒
1.
2.
D Gröne† R Treudler† EM de Villiers‡ R Husak† CE Orfanos† ChC Zouboulis†§ 《Journal of the European Academy of Dermatology and Venereology》2006,20(2):202-205
Cidofovir is an acyclic nucleoside phosphonate with broad-spectrum activity against DNA viruses, including human papilloma virus (HPV). However, data on the efficacy of cidofovir in an immunosuppressive setting remain contradictory. We report for the first time on the promotion of the healing of recalcitrant warts in a patient with myelodysplastic syndrome with intravenous cidofovir treatment. 相似文献
3.
4.
5.
6.
7.
Rui T Marinho Ruth M Pinto Maria L Santos Miguel Carneiro de Moura 《Liver international》2004,24(5):413-418
BACKGROUND: Seroreversion, negativation of anti-hepatitis C virus previously positive, is sometimes found in some chronic hepatitis C-sustained responders (SRs) to antiviral therapy. AIMS: To determine the probability of seroreversion in SR treatment with Interferon and Ribavirin, and lymphocyte T helper (CD4+) reactivity to HCV antigens. METHODS: Thirty SR were followed on average for 54.8 months. Anti-HCV was tested by third generation test. Peripheral blood mononuclear cells (PBMCs) were isolated from venous blood and cultured to evaluate CD4+ proliferation in response to 2 microg/ml of eight HCV recombinant antigens from core, NS3, NS4, NS5 regions. RESULTS: Seroreversion was verified in 23% of patients (7/30), appearing at 47.5+/-24.0 months. The probability of anti-HCV loss in this group was 25% at 56 months after ending therapy. In 57% (4/7), anti-HCV returned to positive. These 7 SR patients with seroreversion also showed weaker CD4+ reactivity in 5% of tests (3/56) than the remaining 23 anti-HCV-positive SRs who showed stronger reactivity in 18% of tests (33/184), P=0.036. CONCLUSIONS: One-quarter of the SR showed seroreversion of anti-HCV and weaker CD4+ specific HCV proliferation than those who remained anti-HCV positive. The data suggest that complete viral eradication is a possible and achievable clinical objective. 相似文献
8.
Antonio Vaz Carneiro 《Revista portuguesa de cardiologia》2004,23(12):1633-1638
The rationale behind screening for asymptomatic coronary artery disease is that it may diagnose advanced disease that, while frequently without symptoms, may present for the first time as sudden death. Identifying significant coronary artery disease would enable intervention against risk factors and, if necessary, preventive revascularization. The most recent evidence shows that screening for coronary artery disease with resting electrocardiogram, exercise tolerance testing or electron-beam computerized tomography in low-risk patients does more harm than good, and should not be performed. This negative recommendation is based on the fact that the use of the aforementioned tests has a negative benefit-harm ratio, because the false-positive rate cancels out any benefit from the occasional detection of real disease, inducing a cascade of further testing (sometimes with angiography) and overdiagnosis of a disease that is not in fact present, with negative psychological and financial consequences, such as increased insurance premiums. We feel that the Portuguese Society of Cardiology should intervene with the institutions performing screening of coronary heart disease in asymptomatic patients, and recommend abandoning a practice that is of little use and, overall, harmful. 相似文献
9.
The receptor tyrosine kinase (RTK) Ret is activated by the formation of a complex consisting of ligands such as glial cell line-derived neurotrophic factor (GDNF) and glycerophosphatidylinositol-anchored coreceptors termed GFRalphas. During activation, Ret translocates into lipid rafts, which is critical for functional responses to GDNF. We found that Ret was rapidly ubiquitinated and degraded in sympathetic neurons when activated with GDNF, but, unlike other RTKs that are trafficked to lysosomes for degradation, Ret was degraded predominantly by the proteasome. After GDNF stimulation, the majority of ubiquitinated Ret was located outside of lipid rafts and Ret was lost predominantly from nonraft membrane domains. Consistent with the predominance of Ret degradation outside of rafts, disruption of lipid rafts in neurons did not alter either the GDNF-dependent ubiquitination or degradation of Ret. GDNF-mediated survival of sympathetic neurons was inhibited by lipid raft depletion, and this inhibitory effect of raft disruption on GDNF-mediated survival was reversed if Ret degradation was blocked via proteasome inhibition. Therefore, lipid rafts sequester Ret away from the degradation machinery located in nonraft membrane domains, such as Cbl family E3 ligases, thereby sustaining Ret signaling. 相似文献
10.
A Martins H Cortez-Pinto P Marques-Vidal N Mendes S Silva N Fatela H Glória R Marinho I Távora F Ramalho M Carneiro de Moura 《Liver international》2006,26(6):680-687
INTRODUCTION: Hepatocellular carcinoma is a leading cause of death from cancer worldwide. Survival of patients depends on tumor extension and liver function, but yet there is no consensual prognostic model. AIMS: To evaluate the influence on survival of pretreatment parameters (clinico-laboratorial, liver function, tumor extension, Okuda and Cancer of the Liver Italian program (CLIP) staging) and treatment modalities. METHODS: We retrospectively analyzed 207 patients, diagnosed between 1993 and 2003. The initial treatment was: surgery--six patients; radiofrequency ablation--21; percutaneous ethanol injection--29; transarterial chemoembolization--49; tamoxifen--49; supportive care alone--53. Factors determining survival were assessed by Kaplan-Meier method and Cox regression models. RESULTS: Median survival was 24 months. In univariate analysis, Child-Pugh classification and Model for end-stage liver disease (MELD) score, portal vein thrombosis (PVT), tumor size, number of lesions, Okuda and CLIP scores were all associated with prognosis (P < 0.001). Alpha-fetoprotein levels were not predictive of survival. Independent predictors of survival were ascites, bilirubin, PVT and therapeutic modalities (P < 0.001). In early stage hepatocellular carcinoma (HCC), survival was similar for both percutaneous ablation modalities, either radiofrequency or ethanol injection (P = NS). In advanced HCC, survival was better in patients receiving tamoxifen than supportive care alone (P < 0.001). CONCLUSION: This study reinforces the importance of baseline liver function (Child-Pugh classification and MELD score) in the survival of patients with HCC, although staging systems allowed the stratification of patients in different prognostic groups. Ascites, bilirubin and PVT were independent pretreatment predictors of survival. All treatments influenced the patient's outcome, whether in early or advanced stages. 相似文献